VivoSim LabsFRA:4OR 39 Current Ratio is 2.44 as of Dec. 2025, which is 80% below its 10-year median of 12.46. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.13. The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, VivoSim Labs ranks worse than 62.74% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. VivoSim Labs's current ratio for the quarter that ended in Dec. 2025 was 2.44.
VivoSim Labs has a current ratio of 2.44. It generally indicates good short-term financial strength.
The historical rank and industry rank for VivoSim Labs's Current Ratio or its related term are showing as below:
FRA:4OR'
s Current Ratio Range Over the Past 10 Years
Min: 0.72 Med: 12.46 Max: 53.26
Current: 2.44
During the past 13 years, VivoSim Labs's highest Current Ratio was 53.26. The lowest was 0.72. And the median was 12.46.
FRA:4OR's Current Ratio is ranked worse than 62.74% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs FRA:4OR: 2.44
VivoSim Labs (FRA:4OR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
VivoSim Labs Current Ratio Related Terms
VivoSim Labs Current Ratio Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs AZTR, GRI, BIXT: Current Ratio Comparison
For the Biotechnology subindustry, VivoSim Labs's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Current Ratio distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Current Ratio of 2.44 as of Dec. 2025. This is 80% below median its historical median of 12.46. Over the past decade, VivoSim Labs' Current Ratio has ranged from 0.72 to 53.26. According to the industry distribution chart, VivoSim Labs ranks #889 out of 1417 companies in the Biotechnology industry, placing it in the top 62.7%.
Is VivoSim Labs' Current Ratio too high?
VivoSim Labs' current Current Ratio of 2.44 is 80% below median its 10-year median of 12.46. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 53.26. The Biotechnology industry median Current Ratio is 3.89. VivoSim Labs' value of 2.44 is 37.3% below this industry median. Based on the distribution chart, VivoSim Labs ranks #889 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Current Ratio compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #889 out of 1417 companies for Current Ratio. This places VivoSim Labs in the lower half of its industry. The industry median Current Ratio is 3.89. VivoSim Labs' value of 2.44 is 37.3% below this benchmark. Historically, VivoSim Labs' own Current Ratio has ranged from 0.72 to 53.26 over the past decade. While the company's 10-year median is 12.46 vs. the industry median of 3.89, VivoSim Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Current Ratio of 2.44 is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Current Ratio is 2.44, which is 80% below median its own 10-year median of 12.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Current Ratio of 2.44. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current Current Ratio is 2.44, which is 80% below median its 10-year median of 12.46 and 37.3% below the Biotechnology industry median of 3.89. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Current Ratio is 2.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.
Key valuation signals for FRA:4OR:
Current Ratio: 2.44 (80% below median its 10-year median of 12.46)
GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
Industry Position: 37.3% below the Biotechnology median (#889 of 1417)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
